Menu

Kropivsek et al., Nature Cancer, 2023

Welcome to our Multiple Myeloma resource.

About us Dashboard Downloads
About

A multiple myeloma study.

Between 2017 and 2021, we, an interdisciplinary team of researchers and clinicians from the ETH Zurich and University Hospital Zurich have been carefully profiling left-over material from bone marrow aspirates of patients suffering from multiple myeloma (MM). The study was published at Nature Cancer.


Kropivsek et al., @ Nature Cancer Over 100 patient samples have been investigated using a variety of complementary technologies, providing unique insights into this cancer. These technologies include our image-based ex vivo drug screening platform, called pharmacoscopy. Pharmacoscopy enables us to measure the drug sensitivity of each individual cell in these samples, to a large panel of possible treatment options. Furthermore, using proteomics, we have measured the abundance of over 5000 proteins in the cancer cells present in each sample. We combine these data with eachother as well as anonymous clinical course of each patient to come to valuable insights.


The purpose of this website is to facilitate the sharing and re-use of our results.


Downloads

Reduce. Reuse. Reanalyse.

Summary tables of our key results can be downloaded here. Please cite Kropivsek et al., Nature Cancer, 2023 if you use any of these data.



The cohort.xlsx

The cohort description, including patient stage, genetics, and matching sample composition.

Pharmacoscopy.xlsx

Drug sensitivity of 101 MM patient samples to 61 drugs and drug combinations.

Tested drug conditions are detailed here.


Proteotyping.xlsx

Normalized protein abundances of 5663 unique proteins for the plasma cells purified from 76 MM patients.

Raw datafiles are available at MassIVE.


Cytokines.xlsx

We profiled the abundance of 64 cytokines in the bone marrow serum for 48 MM patients.

Clinical responses.xlsx

Clinical response data for 34 evaluable patients.

Sample usage.xlsx

An overview of which analyses were performed on each sample.
Faq

Questions and Answers.

Still not clear who we are and what we do? Or do you have other questions? Perhaps your questions are answered below, but don't hesitate to contact us if they're not.

What are you?

We are a publicly funded laboratory headed by Prof. Dr. Berend Snijder at the Institute of Molecular Systems Biology of the ETH Zurich in Switzerland. We are Systems Biologists, which in practice means that we combine large-scale cell biological experimentation with big data analysis and computational modeling. We do this to improve our ability to measure key aspects of cell biology, and to improve our understanding of life in health and disease.


Who funds you?

Our research is supported by public funding, which means we have a strong mandate to give back to society. Our funding includes an SNF Förderungsprofessur and an ERC Starting Grant:
Swiss National Science Foundation European Research Council ETH Zurich


Get in touch.

The MYELOMICS resource is under construction and maintained by the Snijder Lab. Feel free to reach out!